Early-stage oncology startup Boundless Bio files for IPO

Bound­less Bio has filed to go pub­lic as it ap­proach­es ear­ly safe­ty and ef­fi­ca­cy da­ta for its first clin­i­cal at­tempt at a unique take on treat­ing can­cer.

The five-year-old San Diego start­up re­vealed its plans Wednes­day to trade on the Nas­daq as “BOLD.” The move comes as in­vestor sen­ti­ment picks up with a flur­ry of fol­low-on of­fer­ings and re­newed in­ter­est in crossover rounds.

Bound­less, one of the many star­tups in ARCH Ven­ture Part­ners’ sprawl­ing port­fo­lio, had pre­vi­ous­ly raised about $250 mil­lion on the pri­vate side, in­clud­ing a $100 mil­lion Se­ries C last May, short­ly be­fore it brought on ex-EQRx fi­nance chief Ja­mi Ru­bin to run fi­nances.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.